{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:07:20Z","timestamp":1793200040618,"version":"4.5.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T00:00:00Z","timestamp":1672012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100008530","name":"Fondo Europeo de Desarrollo Regional","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>We evaluated the prevalence of transmitted drug resistance (TDR) to integrase strand-transfer inhibitors (INSTIs) and nucleoside\/nucleotide reverse transcriptase inhibitors (NRTIs) and of clinically relevant resistance (CRR) in newly diagnosed people with human immunodeficiency virus (HIV; PWH) naive to antiretroviral therapy (ART) in Europe.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>MeditRes is a consortium that includes ART-naive PWH newly diagnosed in France, Greece, Italy, Portugal, and Spain during 2018\u20132021. Reverse transcriptase and INSTI sequences were provided by participating centers. To evaluate the prevalence of surveillance drug resistance mutations (SDRM), we used the calibrated population resistance tools from the Stanford HIV website. To evaluate CRR, defined as any resistance level \u22653, we used the Stanford HIV Drug Resistance Database v.9.1 algorithm.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 2705 PWH, 72% men, median age of 37 years (interquartile range, 30\u201348); 43.7% were infected by non-B subtypes. The prevalence of INSTI-SDRMs was 0.30% (T66I, T66A, E92Q, E138T, E138K, Y143R, S147G, R263K; all n=1) and the prevalence of NRTI-SDRMs was 5.77% (M184V: 0.85%; M184I: 0.18%; K65R\/N: 0.11%; K70E: 0.07%; L74V\/I: 0.18%; any thymidine analog mutations: 4.36%). INSTI-CRR was 2.33% (0.15% dolutegravir\/bictegravir, 2.29% raltegravir\/elvitegravir) and 1.74% to first-line NRTIs (0.89% tenofovir\/tenofovir alafenamide, 1.74% abacavir, 1.07% lamivudine\/emtricitabine).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We present the most recent data on TDR to integrase-based first-line regimens in Europe. Given the low prevalence of CRR to second-generation integrase inhibitors and to first-line NRTIs during 2018\u20132021, it is unlikely that newly diagnosed PWH in MeditRes countries would present with baseline resistance to a first-line regimen based on second-generation integrase inhibitors.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciac972","type":"journal-article","created":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T11:42:12Z","timestamp":1672054932000},"page":"1628-1635","source":"Crossref","is-referenced-by-count":44,"title":["Transmitted Drug Resistance to Integrase-Based First-Line Human Immunodeficiency Virus Antiretroviral Regimens in Mediterranean Europe"],"prefix":"10.1093","volume":"76","author":[{"given":"Adolfo","family":"de Salazar","sequence":"first","affiliation":[{"name":"Clinical Microbiology Unit, Hospital Universitario Cl\u00ednico San Cecilio, Granada, Instituto de Investigacion Ibs , Granada , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas, CIBERINFEC, Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Vi\u00f1uela","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Unit, Hospital Universitario Cl\u00ednico San Cecilio, Granada, Instituto de Investigacion Ibs , Granada , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Fuentes","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Unit, Hospital Universitario Cl\u00ednico San Cecilio, Granada, Instituto de Investigacion Ibs , Granada , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Teyssou","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9-Salp\u00eatri\u00e8re\u2014Charles Foix, laboratoire de virologie , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Charpentier","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, IAME, UMR1137, Inserm, Laboratoire de Virologie, H\u00f4pital Bichat-Claude Bernard, AP-HP , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidonie","family":"Lambert-Niclot","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pital Saint-Antoine, laboratoire de virologie , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Serrano-Conde","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Unit, Hospital Universitario Cl\u00ednico San Cecilio, Granada, Instituto de Investigacion Ibs , Granada , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pingarilho","sequence":"additional","affiliation":[{"name":"Global Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical\/Universidade Nova de Lisboa , Lisboa , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia","family":"Fabeni","sequence":"additional","affiliation":[{"name":"Laboratory of Virology, INMI \u201cLazzaro Spallanzani\u201d-IRCCS , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"De Monte","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire de Nice, Laboratoire de Virologie , Nice , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Stefic","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire de Tours, Laboratoire de Virologie , Tours , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Federico","family":"Perno","sequence":"additional","affiliation":[{"name":"Multimodal Laboratory Research Department, Children Hospital Bambino Ges\u00f9, IRCCS , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Aguilera","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Unit, Complexo Hospitalario Universitario de Santiago , Santiago de Compostela , Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria de Santiago , Santiago de Compostela , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iker","family":"Falces","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Unit, Hospital Universitario La Paz , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Delgado","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Unit, Hospital Universitario 12 de Octubre , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Centro de Investiga\u00e7\u00e3o Interdisciplinar Egas Moniz, Instituto Universit\u00e1rio Egas Moniz , Almada , Portugal"},{"name":"Laborat\u00f3rio de Biologia Molecular, LMCBM, SPC, Centro Hospitalar Lisboa Ocidental\u2014HEM , Lisboa , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Diogo","sequence":"additional","affiliation":[{"name":"Centro de Investiga\u00e7\u00e3o Interdisciplinar Egas Moniz, Instituto Universit\u00e1rio Egas Moniz , Almada , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perpetua","family":"Gomes","sequence":"additional","affiliation":[{"name":"Centro de Investiga\u00e7\u00e3o Interdisciplinar Egas Moniz, Instituto Universit\u00e1rio Egas Moniz , Almada , Portugal"},{"name":"Laborat\u00f3rio de Biologia Molecular, LMCBM, SPC, Centro Hospitalar Lisboa Ocidental\u2014HEM , Lisboa , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Paraskevis","sequence":"additional","affiliation":[{"name":"Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens , Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Mercedes","family":"Santoro","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Rome \u201cTor Vergata\u201d , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ceccherini-Silberstein","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Rome \u201cTor Vergata\u201d , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Genevi\u00e8ve","family":"Marcelin","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9-Salp\u00eatri\u00e8re\u2014Charles Foix, laboratoire de virologie , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7611-781X","authenticated-orcid":false,"given":"Federico","family":"Garcia","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Unit, Hospital Universitario Cl\u00ednico San Cecilio, Granada, Instituto de Investigacion Ibs , Granada , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas, CIBERINFEC, Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,12,26]]},"reference":[{"key":"2023050318395206100_ciac972-B1"},{"key":"2023050318395206100_ciac972-B2","author":"European AIDS Clinical Society"},{"key":"2023050318395206100_ciac972-B3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/cid\/ciy463","article-title":"Human immunodeficiency virus drug resistance: 2018 recommendations of the International Antiviral Society\u2013USA Panel","volume":"68","author":"G\u00fcnthard","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023050318395206100_ciac972-B4"},{"key":"2023050318395206100_ciac972-B5","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1086\/496984","article-title":"Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis","volume":"41","author":"Sax","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2023050318395206100_ciac972-B6","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1086\/528802","article-title":"Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1\u2013infected subjects","volume":"197","author":"Kuritzkes","year":"2008","journal-title":"J Infect Dis"},{"key":"2023050318395206100_ciac972-B7","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1473-3099(11)70032-9","article-title":"Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study","volume":"11","author":"Wittkop","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"2023050318395206100_ciac972-B8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1056\/NEJMoa013552","article-title":"Antiretroviral-drug resistance among patients recently infected with HIV","volume":"347","author":"Little","year":"2002","journal-title":"N Engl J Med"},{"key":"2023050318395206100_ciac972-B9","article-title":"Antiretroviral resistance testing in HIV-positive people","volume":"11","author":"Aves","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2023050318395206100_ciac972-B10","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/QAI.0000000000002135","article-title":"Effectiveness of transmitted drug resistance testing before initiation of antiretroviral therapy in HIV-positive individuals","volume":"82","author":"Lodi","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023050318395206100_ciac972-B11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3851\/IMP1748","article-title":"Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy","volume":"16","author":"Young","year":"2011","journal-title":"Antivir Ther"},{"key":"2023050318395206100_ciac972-B12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3851\/IMP1749","article-title":"Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient","volume":"16","author":"Boyd","year":"2011","journal-title":"Antivir Ther"},{"key":"2023050318395206100_ciac972-B13","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1093\/jac\/dkv049","article-title":"HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007\u201312: impact on susceptibility to first-line strategies","volume":"70","author":"Frange","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2023050318395206100_ciac972-B14","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1093\/jac\/dkv243","article-title":"Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades","volume":"70","author":"Doyle","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2023050318395206100_ciac972-B15","first-page":"478","volume-title":"Conference on Retroviruses and Opportunistic Infections","author":"Hernandez","year":"2017"},{"key":"2023050318395206100_ciac972-B16","volume-title":"Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"Volpe","year":"2015"},{"key":"2023050318395206100_ciac972-B17","doi-asserted-by":"crossref","first-page":"e4724","DOI":"10.1371\/journal.pone.0004724","article-title":"Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update","volume":"4","author":"Bennett","year":"2009","journal-title":"PLoS One"},{"key":"2023050318395206100_ciac972-B18","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jac\/dkz417","article-title":"Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance","volume":"75","author":"Tzou","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2023050318395206100_ciac972-B19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/v14010071","article-title":"Epidemiology and transmitted HIV-1 drug resistance among treatment-naive individuals in Israel, 2010\u20132018","volume":"14","author":"Wagner","year":"2022","journal-title":"Viruses"},{"key":"2023050318395206100_ciac972-B20","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/cid\/ciab583","article-title":"Transmitted drug resistance among human immunodeficiency virus (HIV)-1 diagnoses in the United States, 2014\u20132018","volume":"74","author":"McClung","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023050318395206100_ciac972-B21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1556\/030.2021.01433","article-title":"Prevalence of resistance mutations associated with integrase inhibitors in therapy-naive HIV-positive patients in Hungary","volume":"68","author":"\u00c1y","year":"2021","journal-title":"Acta Microbiol Immunol Hung"},{"key":"2023050318395206100_ciac972-B22","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1089\/aid.2020.0261","article-title":"Integrase strand transfer inhibitor resistance in integrase strand transfer inhibitor-naive persons","volume":"37","author":"Bailey","year":"2021","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2023050318395206100_ciac972-B23","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2147\/DDDT.S286863","article-title":"Low frequency of integrase inhibitor resistance mutations among therapy-naive HIV patients in southeast China","volume":"15","author":"Lai","year":"2021","journal-title":"DDDT"},{"key":"2023050318395206100_ciac972-B24","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/hiv.13038","article-title":"Transmitted HIV-1 drug resistance in a large international cohort using next-generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) study","volume":"22","author":"Baxter","year":"2021","journal-title":"HIV Med"},{"key":"2023050318395206100_ciac972-B25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/hiv.12956","article-title":"Transmitted drug resistance to NRTIs and risk of virological failure in na\u00efve patients treated with integrase inhibitors","volume":"22","author":"Borghetti","year":"2021","journal-title":"HIV Med"},{"key":"2023050318395206100_ciac972-B26","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1093\/jac\/dkaa349","article-title":"Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping","volume":"75","author":"Casadell\u00e0","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2023050318395206100_ciac972-B27","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1093\/jac\/dkaa309","article-title":"Surveillance of HIV-1 transmitted integrase strand transfer inhibitor resistance in the UK","volume":"75","author":"Mbisa","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2023050318395206100_ciac972-B28","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/hiv.12640","article-title":"Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016","volume":"19","author":"Rossetti","year":"2018","journal-title":"HIV Med"},{"key":"2023050318395206100_ciac972-B29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090710","article-title":"Clinically relevant transmitted drug resistance to first line antiretroviral drugs and implications for recommendations","volume":"9","author":"Monge","year":"2014","journal-title":"PLoS One"},{"key":"2023050318395206100_ciac972-B30","doi-asserted-by":"crossref","first-page":"105.e1","DOI":"10.1016\/j.cmi.2014.08.007","article-title":"Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007\u20132012)","volume":"21","author":"Monge","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"2023050318395206100_ciac972-B31","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/jac\/dkz067","article-title":"Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice","volume":"74","author":"Alvarez","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023050318395206100_ciac972-B32","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/cid\/civ963","article-title":"Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe","volume":"62","author":"Hofstra","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2023050318395206100_ciac972-B33","volume-title":"When to initiate antiretroviral therapy, with protocol for rapid initiation [internet]","author":"Radix","year":"2022"},{"key":"2023050318395206100_ciac972-B34","volume-title":"Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy, July 2017","author":"World Health Organization","year":"2017"},{"key":"2023050318395206100_ciac972-B35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hiv.12708","article-title":"Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps","volume":"20","author":"Boyd","year":"2019","journal-title":"HIV Med"},{"key":"2023050318395206100_ciac972-B36","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.24875\/AIDSRev.M19000027","article-title":"Rapid initiation of antiretroviral therapy after HIV diagnosis","volume":"21","author":"Garc\u00eda Deltoro","year":"2019","journal-title":"AIDSRev"},{"key":"2023050318395206100_ciac972-B37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11908-021-00750-5","article-title":"Evidence regarding rapid initiation of antiretroviral therapy in patients living with HIV","volume":"23","author":"Michienzi","year":"2021","journal-title":"Curr Infect Dis Rep"},{"key":"2023050318395206100_ciac972-B38","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/jac\/dku377","article-title":"Infection with the frequently transmitted HIV-1 M41L variant has no influence on selection of tenofovir resistance","volume":"70","author":"Pingen","year":"2015","journal-title":"J Antimicrob Chemother"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciac972\/49155803\/ciac972.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/9\/1628\/50189368\/ciac972.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/9\/1628\/50189368\/ciac972.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T18:41:25Z","timestamp":1683139285000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/76\/9\/1628\/6960884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,26]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,12,26]]},"published-print":{"date-parts":[[2023,5,3]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac972","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2022,12,26]]}}}